Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, June 24, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Bolt Biotherapeutics, Inc. (“Bolt” or the “Company”) (NASDAQ: BOLT) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Bolt investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
On May 14, 2024, Bolt announced in a press release that the Company would “cease further development of trastuzumab imbotolimod (BDC-1001)”, Bolt’s lead asset, “and reduce workforce by approximately 50%”. Following Bolt’s announcement, multiple analysts downgraded the Company’s stock.
On this news, Bolt’s stock price fell $00.49 per share, or more than 37.12%, to close at $00.83 per share on May 15, 2024.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com
Attorney Advertising
